Equity Research Report: Global Health Limited (Medanta)
Date: February 4, 2026 (Analysis based on Latest Q3 FY26 Results)
Sector: Healthcare / Hospitals
CMP (Current Market Price): ₹1,110 – ₹1,125 Range
1️⃣ Business Model & Work (Company Kya Karti Hai?)
Global Health Limited, jo “Medanta” brand name se operate karti hai, India ki leading tertiary aur quaternary care hospital chains me se ek hai. Iski shuruat world-renowned heart surgeon Dr. Naresh Trehan ne ki thi.
- Core Business: High-end complex surgeries aur medical treatment (Cardiology, Oncology, Neuro, Liver Transplant).
- Unique Selling Proposition (USP): “Doctor-Led Model”. Unlike corporate hospitals (Apollo/Max) jo management-run hote hain, Medanta hospitals senior doctors dwara lead kiye jate hain, jisse clinical excellence high rehti hai.
- Key Locations:
- Gurugram (Flagship): Ye inka sabse bada revenue contributor hai.
- Lucknow & Patna: Ye naye growth engines hain jo tezi se ramp-up ho rahe hain.
- Noida (New): November 2025 me naya 550-bed hospital launch hua hai.
- Indore & Ranchi: Smaller centers.
- Revenue Mix: Majority revenue In-patient services (hospital admission) se aata hai. International patients se bhi accha contribution milta hai.
2️⃣ Industry & Sector Analysis
- Sector Status: Healthcare India me Secular Growth phase me hai. Chronic diseases (heart, cancer) badh rahe hain aur insurance penetration improve ho raha hai.
- Cyclical or Secular?: Secular. Mandi (Recession) ka asar healthcare par kam hota hai kyunki ye essential service hai.
- Growth Drivers:
- Medical Tourism: Videshi mareez India aa rahe hain (Cost benefit).
- Aging Population: India me senior citizens ki tadad badh rahi hai.
- Tier-2 Expansion: Lucknow aur Patna jaise shehron me demand supply se kahin jyada hai.
- Major Competitors: Apollo Hospitals, Max Healthcare, Fortis Healthcare, Narayana Hrudayalaya.
3️⃣ Latest Financial Performance (STRICT DATA RULE)
Data Source: BSE Filings / Latest Q3 FY26 Results announced Feb 4, 2026
⚠️ RESULT UPDATE (Q3 FY26 – Released Today):
Aaj (4 Feb 2026) company ne apne Q3 FY26 ke results announce kiye hain. Results kamzor (weak) dikh rahe hain due to exceptional items and operational costs.
| Metrics (Consolidated) | FY 2023 | FY 2024 | FY 2025 | Q2 FY26 | Q3 FY26 (Latest) |
| Revenue (₹ Cr) | 2,694 | 3,275 | 3,771 | 1,099 | 1,119 |
| Operating Profit (EBITDA) | 602 | 831 | 956 | ~280 | ~245-250 |
| EBITDA Margin | 22% | 25% | 25% | ~25% | ~22% |
| Net Profit (PAT) | 326 | 478 | 481 | 158 | 95 |
| EPS (in ₹) | 12.1 | 17.8 | 17.9 | 5.89 | 3.54 |
- Key Observations:
- Revenue Growth: Revenue flat/marginal badha hai (₹1,119 Cr vs ₹1,099 Cr in Q2). Noida hospital start hone se revenue add hua hai lekin abhi contribution chhota hai.
- Profit Crash: Net Profit Q3 me ~33% YoY girkar ₹95 Cr reh gaya hai. Iska main karan ek Exceptional Item (₹36 Cr approx) aur naye hospital (Noida) ki shuruati costs hain.
- Margins Pressure: Naye hospitals shuru karte waqt margins temporary girte hain (operational leverage aane me time lagta hai).
4️⃣ Management & Shareholding (Latest Dec 2025)
- Promoter Holding:33.01% (Dr. Naresh Trehan & Family).
- Note: Promoter holding stable hai. Key Man Risk hamesha rehta hai kyunki brand Dr. Trehan ke naam se juda hai.
- FIIs (Foreign Investors): ~10.53%. Slight decline observed in recent quarters.
- DIIs (Domestic Investors): ~13-14%. Mutual Funds ne stake badhaya hai (Positive sign).
- Management Quality: World-class clinical leadership. Governance strong hai, lekin hospital expansion execution par nazar rakhni hogi.
5️⃣ Valuation (Latest Market Data Only)
- Current Market Price (CMP): ₹1,121 (approx)
- Market Cap: ~₹30,250 Cr
| Metric | Value (Approx) | Comment |
| P/E Ratio (TTM) | ~54x – 60x | Results weak aane se PE aur mehenga ho gaya hai. |
| P/B Ratio | ~8.0x | Industry standards se high premium par hai. |
| EV / EBITDA | ~30x | Apollo aur Max ke barabar ya thoda sasta hai. |
- Peer Comparison:
- Max Healthcare aur Apollo 60-70x PE par trade karte hain. Medanta (~55x) valuation wise thoda “reasonable” lag sakta hai lekin growth slow hone par ye bhi mehenga lagega.
- Fair Value View:
- Current numbers (Q3 earnings drop) ke hisab se stock Fully Valued / Expensive hai. Market future growth (Lucknow/Noida maturity) ke liye premium pay kar raha hai.
6️⃣ Future Growth Triggers (3–5 Years)
- Noida Hospital Ramp-up: Nov 2025 me khula 550-bed ka Noida hospital agle 2-3 saal me bada revenue driver banega. Jab ye mature hoga, margins wapas 25% level par aayenge.
- Mumbai Expansion: Company ne Mumbai hospital ke liye beds 500 se badhakar 750 kar diye hain. Ye ek bada capex (~₹1,500 Cr) hai, lekin long term me game changer hoga.
- Lucknow & Patna Maturity: Ye dono units ab “Cash Cow” banne ki raah par hain. Jaise-jaise occupancy badhegi, profit exponential rate se badhega.
- Doctor Retention: Medanta ka model doctors ko partner banane ka hai, jo attrition (doctors ka chhod kar jana) kam karta hai.
7️⃣ Present Situation (Current Outlook)
- Stock Phase: Neutral / Weak. Q3 results (profit drop) ke karan stock me short-term selling pressure aa sakta hai.
- Recent Development: Noida hospital launch positive hai long term ke liye, lekin short term me P&L par cost ka bojh dalega.
- Outlook:
- Short-Term (3-6 Months): Range-bound (₹1,000 – ₹1,200). Earnings recovery ka wait karega market.
- Long-Term: Bullish. Capital allocation perfect hai (Tier-1 cities + High density areas).
8️⃣ Risk & Red Flags ⚠️
- Key Man Risk: Brand “Medanta” Dr. Trehan ki personal reputation par bahut dependent hai. Succession planning (next leader kaun?) ek important sawal hai.
- New Hospital Drag: Naye hospitals (Noida, Mumbai) shuru ke 1-2 saal loss karte hain. Isse overall company ka margin dab sakta hai.
- Competition: NCR (Delhi/Gurugram/Noida) me Apollo, Max aur Fortis aggressive expansion kar rahe hain. Market share protect karna mushkil ho sakta hai.
- Regulatory Risk: Govt agar price capping (stents, surgeries par) lagati hai, to margins hit honge.
9️⃣ Final Verdict
- Business Quality: ⭐⭐⭐⭐⭐ (Best-in-class clinical facilities).
- Recent Performance: ⭐⭐ (Q3 weak due to exceptional items).
- Valuation: ⭐⭐⭐ (Expensive, prices in future perfection).
Recommendation Summary:
- Short-Term Traders: AVOID. Q3 result reaction negative ho sakta hai. Momentum abhi weak hai.
- Conservative Investors: WAIT. Valuation ~55x PE hai. Agar stock ₹950 – ₹1,000 ke aas-paas mile (market correction me), tab safe entry hogi.
- Long-Term Investors (5 Years): SIP/Accumulate. Medanta ek “Compounding Machine” hai. Aaj ki cost (Noida hospital) kal ka profit hai. Agar aap 5 saal hold kar sakte hain, to current dips par khareed sakte hain.
Final Word: Medanta ek marathon runner hai. Q3 ka profit drop ek “speed breaker” hai, road block nahi. Long-term story (Patna, Lucknow, Noida) abhi play out hona baki hai.
Disclaimer: Ye article sirf educational purpose ke liye hai. Kisi bhi nivesh se pehle apne Financial Advisor se salah zarur lein.